Publication: Response
| cris.lastimport.scopus | 2025-05-14T22:38:56Z | |
| cris.virtual.department | Clinical Pharmacy | |
| cris.virtual.department | Pharmacy | |
| cris.virtual.department | School of Pharmacy | |
| cris.virtual.department | Pharmacy-NTUH | |
| cris.virtual.department | Internal Medicine | |
| cris.virtual.department | Internal Medicine-NTUH | |
| cris.virtual.orcid | 0000-0002-8249-7481 | |
| cris.virtual.orcid | 0000-0002-7718-0594 | |
| cris.virtualsource.department | 73278856-f8bb-4d3b-bcea-81172faf19bc | |
| cris.virtualsource.department | 73278856-f8bb-4d3b-bcea-81172faf19bc | |
| cris.virtualsource.department | 73278856-f8bb-4d3b-bcea-81172faf19bc | |
| cris.virtualsource.department | 73278856-f8bb-4d3b-bcea-81172faf19bc | |
| cris.virtualsource.department | 3c563053-8075-4901-a4d2-fa290b089cbc | |
| cris.virtualsource.department | 3c563053-8075-4901-a4d2-fa290b089cbc | |
| cris.virtualsource.orcid | 73278856-f8bb-4d3b-bcea-81172faf19bc | |
| cris.virtualsource.orcid | 3c563053-8075-4901-a4d2-fa290b089cbc | |
| dc.contributor.author | FANG-JU LIN | en_US |
| dc.contributor.author | Chang, Ting-Yu | en_US |
| dc.contributor.author | JUNG-YIEN CHIEN | en_US |
| dc.date.accessioned | 2020-10-12T10:19:25Z | |
| dc.date.available | 2020-10-12T10:19:25Z | |
| dc.date.issued | 2020-06 | |
| dc.identifier.doi | 10.1016/j.chest.2020.02.055 | |
| dc.identifier.isi | WOS:000539236600050 | |
| dc.identifier.issn | 00123692 | |
| dc.identifier.pmid | 32505317 | |
| dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/516782 | |
| dc.language.iso | animation | en_US |
| dc.publisher | ELSEVIER | en_US |
| dc.relation.ispartof | Chest | en_US |
| dc.relation.journalissue | 6 | en_US |
| dc.relation.journalvolume | 157 | en_US |
| dc.relation.pageend | 1684 | en_US |
| dc.relation.pages | 1684 | en_US |
| dc.subject.classification | [SDGs]SDG3 | |
| dc.subject.other | beta 2 adrenergic receptor stimulating agent; corticosteroid; fluticasone propionate plus salmeterol; corticosteroid; chronic obstructive lung disease; disease exacerbation; disease severity; drug efficacy; drug safety; drug use; eosinophil count; human; Letter; medical decision making; outcome assessment; pneumonia; priority journal; risk factor; scoring system; treatment outcome; chronic obstructive lung disease; Adrenal Cortex Hormones; Humans; Pulmonary Disease, Chronic Obstructive | |
| dc.title | Response | en_US |
| dc.type | letter | en_US |
| dspace.entity.type | Publication |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: